The company is a global innovative pharmaceutical company focusing on cancer and metabolic diseases. With the mission of “creating good medicine and helping the world”, the company focuses on providing patients with effective, safe, and affordable drugs, and is committed to developing and producing innovative drugs that meet major clinical needs and have global benefits. The company is an innovation-driven international innovative pharmaceutical company. Based on platforms such as PROTAC technology for targeted protein degradation and deuteration technology, the company focuses on research and development of innovative drugs in therapeutic fields such as cancer and metabolic diseases with significant market potential. Main products: HC-1119, HP518, HP568, HP501, HP515, HP537 and HP560. Corporate honors: 2019 China's Chemical Research and Development Strength Ranking TOP100, 2020 China's New Health Force · New Chemical Formulation Industry New Power Enterprise, 100 Key Cultivating Enterprises for the New Economy in Chengdu, etc. 2022 Top 30 innovative Chinese small molecule pharmaceutical companies; 2023 “Rong Piao Cup”; 2024 Chengdu Enterprise Technology Center; 2023 Tianfu Emei Plan; 2024 Chinese Pharmaceutical R&D Ranking Top 100 Chemical Drug List Top 100; 2023 Top 30 Chinese Small Molecule Pharmaceutical Companies Innovation Power Top 30; Chengdu High-tech Zone “Golden Panda Future Star” · Enterprise Key Core Technology Award; 2024 Typical Practice Case of Listed Company Board of Directors; 2024 Outstanding Practice Case of Listed Company Directors; Second Prize of the First Postdoctoral Innovation and Entrepreneurship Competition.